MicroPort® NeuroTech Completes First Implantation of NUMEN® Coil Embolization System in Chile, Marking Their Debut in an Overseas Market

Puerto Montt, Chile, 03 September 2021 — The NUMEN® Coil Embolization System (NUMEN®), developed by MicroPort NeuroTech (Shanghai) Co., Ltd. (MicroPort® NeuroTech) has been implanted in a patient in Chile, marking not only the first implantation of NUMEN® in an overseas market, but also the debut of MicroPort® NeuroTech products outside of China.

The surgery, which was led by by Dr. Arturo Alonso Gómez and Dr. Andrea Leonor Pérez Migueles from the Puerto Montt Hospital, was perfomred on a 49-year-old female patient suffering from a recurring dural arteriovenous fistula (DAVF). The surgical team were able to successfully eliminate flow through the arteriovenous fistula by filling it with NUMEN® Coils. All indicators were favorable after the procedure, and the patient reported that symptoms had disappeared. The excellent pushability, trackability and detachment performance of NUMEN® were commended by the surgical team.

Zhiyong Xie, President of MicroPort® NeuroTech, commented, “Stroke has been a serious threat to the health of human beings worldwide due to its high incapacitation and mortality rates. Coil embolization is a mainstream treatment option for stroke. The first implantation of NUMEN® in an overseas market demonstrates the recognition of MicroPort® NeuroTech products by doctors abroad.”

By filling the NUMEN® coil into the aneurysm to form thrombus through a minimally invasive approach, it can block blood flow inside the aneurysm, reduce intra-aneurysm pressure and lower the possibility of rupture, thus embolizing the aneurysm in the medium to long term and avoiding the risk of craniotomy. NUMEN® features an ultra-fine platinum-tungsten coil and a unique three-dimensional structure that offers a combination of flexibility and support, minimizing pressure on the aneurysm wall and ensuring safe embolization. It can be used in aneurysms of different shapes, as well as for the occlusion of arteriovenous fistulas. The NUMEN® Coil Embolization System, with its stable embolization and dense packing, is available in various sizes, allowing doctors to select the most appropriate coil based on each patient’s condition.

The NUMEN® Coil Embolization System was approved for the Chinese market in September 2020 and received the CE Mark certification in May 2021.

About MicroPort NeuroTech (Shanghai) Co., Ltd

MicroPort NeuroTech (Shanghai) Co., Ltd. (MicroPort® NeuroTech) is a subsidiary of MicroPort Scientific Corporation (00853.HK). Founded in 2012, MicroPort® NeuroTech is a high-end medical device company focused on neuro-intervention, that provides a range of neuro-interventional products to treat a variety of brain conditions. In the future, MicroPort® NeuroTech will continue to enhance comprehensive cooperation with clinical experts overseas and further expand into global markets, to make our independently-developed products available to more doctors and patients worldwide and to provide inclusive medical solutions for the treatment of stroke and other brain conditions.